Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen, Eisai, and all other drug companies seeking FDA accelerated approval for a class of Alzheimer's drugs known as monoclonal antibodies would fall under Medicare's decision to pay for the ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Eisai shares climbed 3.6% in Tokyo afternoon trade while Biogen shares were 0.9% higher in after-hours trade. They have jumped some 60% and 47% respectively since the announcement of the trial's ...

Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better.

Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial.